136 related articles for article (PubMed ID: 10589787)
1. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
3. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
4. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
5. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
6. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes.
Huang SK; Stauffer PR; Hong K; Guo JW; Phillips TL; Huang A; Papahadjopoulos D
Cancer Res; 1994 Apr; 54(8):2186-91. PubMed ID: 8174126
[TBL] [Abstract][Full Text] [Related]
7. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Vasey PA; Kaye SB; Morrison R; Twelves C; Wilson P; Duncan R; Thomson AH; Murray LS; Hilditch TE; Murray T; Burtles S; Fraier D; Frigerio E; Cassidy J
Clin Cancer Res; 1999 Jan; 5(1):83-94. PubMed ID: 9918206
[TBL] [Abstract][Full Text] [Related]
10. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
11. Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.
Sadzuka Y; Sugiyama T; Suzuki H; Sawanishi H; Miyamoto K
Toxicol Lett; 2004 May; 150(3):341-9. PubMed ID: 15110086
[TBL] [Abstract][Full Text] [Related]
12. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
13. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
[TBL] [Abstract][Full Text] [Related]
14. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
17. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
19. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
20. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice].
Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L
Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]